Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design
- PMID: 8260445
- DOI: 10.1016/0920-9964(93)90061-m
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design
Abstract
The goal of this study was to assess the time course of change in psychopathology and dyskinesia after neuroleptic withdrawal. Fifteen DSM-III schizophrenic patients were abruptly withdrawn in a double-blind fashion from stable haloperidol treatment. Weekly ratings of dyskinesia and psychopathology were performed for 4 weeks post-withdrawal. There was an overall increase in dyskinesia ratings over the 4-week period (p < 0.05) beginning in week 2, with dyskinetic movements of the fingers showing the most significant increase (p < 0.001). There were no overall changes in psychopathology, though the group appeared to be bimodal with 6 of the 15 patients showing a significant relapse in psychotic symptoms. Neither baseline TD nor psychotic relapse significantly interacted with change in TD over time. These schizophrenic patients showed an increase in global dyskinesia rating early within four weeks of neuroleptic withdrawal. This time course did not appear to be associated with reemergence of psychopathology which occurred later. A significant minority of patients relapsed within this time period. This suggests the relative safety of brief periods of neuroleptic withdrawal for carefully selected patients in a controlled setting with specific goals (e.g., for evaluation or in preparation for clozapine) and the need to further understand who is at risk for rapid relapse.
Similar articles
-
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.J Clin Psychiatry. 1990 Aug;51(8):319-21. J Clin Psychiatry. 1990. PMID: 1974249 Clinical Trial.
-
Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.Arch Gen Psychiatry. 1984 Nov;41(11):1030-5. doi: 10.1001/archpsyc.1983.01790220020003. Arch Gen Psychiatry. 1984. PMID: 6149737 Clinical Trial.
-
Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.Psychiatry Res. 1992 Sep;43(3):287-98. doi: 10.1016/0165-1781(92)90061-7. Psychiatry Res. 1992. PMID: 1438625 Clinical Trial.
-
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.J Clin Psychiatry. 2000;61 Suppl 4:21-6. J Clin Psychiatry. 2000. PMID: 10739327 Review.
-
Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.J Clin Psychiatry. 1998 Sep;59(9):472-7. doi: 10.4088/jcp.v59n0906. J Clin Psychiatry. 1998. PMID: 9771818 Review.
Cited by
-
Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.Paediatr Child Health. 2011 Nov;16(9):590-8. Paediatr Child Health. 2011. PMID: 23115503 Free PMC article.
-
Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers.Clin Transl Sci. 2023 Mar;16(3):512-523. doi: 10.1111/cts.13466. Epub 2022 Dec 27. Clin Transl Sci. 2023. PMID: 36514192 Free PMC article. Clinical Trial.
-
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.Schizophr Bull. 2014 Mar;40(2):341-50. doi: 10.1093/schbul/sbt236. Epub 2014 Jan 24. Schizophr Bull. 2014. PMID: 24464874 Free PMC article.
-
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD000459. doi: 10.1002/14651858.CD000459.pub3. Cochrane Database Syst Rev. 2018. PMID: 29409162 Free PMC article.
-
Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxième génération chez les enfants et les adolescents.Paediatr Child Health. 2012 Oct;17(Suppl B):22B-30B. Paediatr Child Health. 2012. PMID: 24082814 Free PMC article. French.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical